This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
79
Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
Placebo was supplied in vials with solution for subcutaneous injection.
Novartis Investigative Site
Arnaud de Villeneuve, France
Novartis Investigative Site
Béthune, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Clamart, France
Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils
Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the FcεRI receptors expression of blood basophils (mean fluorescence intensity(MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.
Time frame: Baseline and 16 weeks
Change From Baseline in the Expression of FcεRI Receptors of Dendritic Cells
Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the FcεRI receptors expression of dendritic cells (mean fluorescence intensity (MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.
Time frame: Baseline and 16 weeks
Change in Fractional Exhaled Nitric Oxide (FeNO)
FeNO was measured at baseline, and after 4, 8, 12 and 16 weeks of treatment. Absolute change in FeNO was expressed at each time point versus baseline value.
Time frame: Baseline and 4, 8, 12 and 16 weeks
Change From Baseline in Induced Sputum Eosinophil Count
The induced sputum eosinophil count was measured in a subset of patients in selected centers. Sputum samples were collected at screening and Week 16. Sputum eosinophil count was expressed as a percentage of total nonsquamous cells. Absolute change in sputum eosinophil count was expressed versus baseline value.
Time frame: Baseline and 16 weeks
Change From Baseline in Score of the Shortened Version of the Asthma Control Questionnaire (Symptoms Plus Short-acting β2-agonist)
The shortened version of the asthma control questionnaire (symptoms plus β2-agonist) consists of 6 subscores (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze and rescue short-acting β2-agonist use) between 0 and 6 (0 = no impairment; 6 = maximum impairment) and a total score between 0 and 6 (subscores mean value). Absolute change in total score and subscores count was expressed versus baseline value. A decrease in score indicates improvement.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Suresnes, France
Novartis Investigative Site
Toulouse, France
Time frame: Baseline and 16 weeks
Change From Baseline in Nasal Symptom Global Score and Individual Components
Nasal symptom score calculated from six scales assessing the nasal symptom severity (sneezing, runny nose, congestion, itchy nose, postnasal drip and nasal symptoms overall). These six scores were rated on a scale from 1 to 7, with 7 being the worst rating. Absolute changes in these six scores were expressed versus baseline values. A negative change indicates improvement. The range of the global score was from 1 to 7, since this is the mean value of all the subscores.
Time frame: Baseline and 16 weeks
Physician and Patient Global Evaluation of Treatment Effectiveness
The GETE is an assessment of asthma symptoms controlled in response to asthma treatment. The evaluation was performed independently by both investigator and patient using the same 5 point scale. The scale points are: excellent, good, moderate, poor and worsening. A good or excellent response is suggested as a means of defining a patient who has responded to treatment.
Time frame: 16 weeks
Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to 16 Weeks
Spirometry was conducted according to internationally accepted standards. At least three maneuvers were performed at each sampling timepoint. The FEV1 recorded was taken from the maneuver obtained from the single best test curve. The best test curve was defined as the spirogram that gave the largest FEV1.
Time frame: Baseline and 16 weeks
Number of Patients With at Least One Asthma-related Event Over 16 Weeks
Asthma-related events were: unscheduled medical visits, emergency room visits and hospitalizations. Details of exacerbations requiring oral or IV corticosteroids were recorded at each visit.
Time frame: 16 weeks